Adam Stewart, MBBS PhD

Other Articles

1. Stewart A, Graves B, Hajkowicz K, Ta K, Paterson DL The use of therapeutic drug monitoring to optimise treatment of carbapenem resistant Enterobacter osteomyelitis. Microb Drug Resist 2015.
2. Stewart A, Armstrong M, Graves S, Hajkowicz, K Epidemiology and Characteristics of Rickettsia australis (Queensland Tick Typhus) Infection in Hospitalized Patients in North Brisbane, Australia. Trop. Med. Infect. Dis. 2017.
3. Stewart A, Armstrong M, Graves S, Hajkowicz K Rickettsia australis and Queensland Tick Typhus: a rickettsial Spotted Fever Group infection in Australia. Am J Trop Med Hyg. 2017.
4. Stewart A, Armstrong M, Graves S, Hajkowicz K Clinical manifestations and outcomes of Rickettsia australis infection: A 15-year retrospective study of hospitalized patients. Trop. Med. Infect. Dis. 2017.
5. Stewart A, Roberts JA, Wallis SC, Allworth AM, Legg A, McCarthy KL Evidence of clinical response and stability of ceftolozane/tazobactam used to treat a carbapenem-resistant Pseudomonas aeruginosa lung abscess on an outpatient antimicrobial program. Int J Antimicrob Agents. 2018.
6. Stewart A, Hajkowicz K Heterogeneity in skin manifestations of spotted fever group rickettsial infection in Australia. Australas J Dermatol. 2018.
7. Stewart A, Harris PN, Henderson A, Paterson DL Treatment of Infections with OXA-48- Producing Enterobacteraciae. Antimicrob Agents Chemother. 2018.
8. Stewart A, Sowden D, Caffery M, Bint M, Broom J Rhodococcus equi infection; a diverse spectrum of disease. IDCases. 2019.
9. Stewart A Disseminated Mycobacterium intracellulare from a deep cutaneous infection. Int J Mycobacteriol. 2019.
10. Stewart A, Sowden D, Sloss A, Broom J Inflammatory bowel disease masquerading as traveller’s diarrhoea. Intern Med J. 2019.
11. Stewart A, Broom J, Sowden D, Hollett P Acute kidney injury in acute Q fever. Intern Med J. 2019.
12. Stewart A, Wright H, Hajkowicz K The rise and rise of antimicrobial resistance in Gram- negative bacteria. Microbiology Australia. 2019.
13. Stewart A, Harris PNA, Chatfield M, Evans SR, van Duin D, Paterson DL Modern clinician- initiated clinical trials to determine optimal therapy for multi-drug resistant Gram-negative infections. Clinical Infectious Diseases. 2019.
14. McNamara J, Avent M, Stewart A, Kwan C, Paterson DL Evaluation of quick sequential organ failure assessment and systemic inflammatory response syndrome in patients with gram negative bloodstream infection. Infect Dis Health. 2020.
15. Paterson DL, Isler B, Stewart A New Treatment Options for Multiresistant Gram Negatives. Curr Opin Infect Dis. 2020.
16. Stewart A, Harris PNA, Henderson A, Schembri MA, Paterson DL Oral cephalosporin and beta-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. J Antimicrob Chemother. 2020.
17. Stewart A, Wright H Initiating tuberculosis treatment at end of life – balancing patient and infection control interests. Infect Dis Health. 2020.
18. Stewart A, Burnard D, Sowden D, McMillan Whole genome sequencing for antimicrobial resistance mechanisms, virulence factors and clonality in invasive Streptococcus agalactiae blood culture isolates recovered in Australia. Pathology. 2020.
19. Isler B, Kidd T, Stewart A, Harris P, Paterson DL Achromobacter Infections and Treatment Options. Antimicrob Agents Chemother. 2020.
20. Isler B, Ezure Y, Romero JG, Stewart A, Paterson DL Is ceftazidime/avibactam an option for serious infections due to ESBL and AmpC producing Enterobacterales?: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2020.
21. Chung J, McCarthy KL, Redmond A, Butler J, Scott AP, Stewart A Listeria monocytogenes brain abscess as a late complication of allogeneic hematopoietic stem cell transplantation. Intern Med J. 2020.
22. Isler B, Harris PNA, Stewart A, Paterson DL An Update on Cefepime and its Future Role in Combination with Novel β-Lactamase Inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother. 2020.
23. Stewart A, Satlin MJ, Schlebusch S, Isler B, Forde BM, Paterson DL, Harris PNA Completing the picture – Capturing the resistome in antibiotic clinical trials. Clinical Infectious Diseases. 2020.
24. Stewart A, Lane SW Just as good but better tolerated: Posaconazole as first-line therapy for invasive aspergillosis. The Hematologist. 2021.
25. Henderson A, Bursle E, Stewart A, Harris P, Paterson D, Chatfield M, Paul M, Dickstein Y, Rodriguez-Baño J, Turnidge J, Kahlmeter G A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to Gram negative pathogens. Clin Microbiol Infect. 2021.
26. Stewart A, Price E, Schabacker K, Birikmen M, Harris PNA, Choong K, Subedi S, Sarovich DS Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae in Southeast Queensland, Australia. Antimicrob Agents Chemother. 2021.
27. Stewart A, Harris PNA, Chatfield M, Littleford RL, Paterson DL Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial. Trials 2021.
28. Stewart A, Sinclair H, Chapman P, Baboolal K, Barber BE, Townsend S Cryptococcus neoformans infection as a cause of severe hyperammonemia and encephalopathy. Intern Med J. 2021.
29. Peri A, Stewart A, Hume A, Irwin A, Harris PNA New microbiological techniques for the diagnosis of bacterial infections and sepsis in ICU including point of care. Curr Infect Dis Rep. 2021.
30. Stewart A, Paterson DL How urgent is the need for new antifungals? Expert Opin Pharmacother. 2021.
31. Stewart A, Baidya S, Daly J, Scott AP Prolonged granulocyte transfusions sourced from buffy coats used to treat Aspergillus spp. infection in chronic granulomatous disease. Pathology. 2021.
32. Stewart A, Cottrell K, Henderson A, Vemuri K, Bauer MJ, Paterson DL, Harris PNA In vitro activity of Cefotetan against ESBL-producing E. coli and K. pneumoniae bloodstream isolates from the MERINO trial. Microbiol Spectr. 2021.
33. Christensen J, O’Callaghan K, Sinclair H, Hawke K, Love A, Hajkowicz K, Stewart A Risk factors, Treatment and Outcomes of Subacute Thyroiditis Secondary to COVID-19: A Systematic Review. Intern Med J. 2021.
34. Stewart A, Paterson DL, Young B et al Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC beta-lactamase producing Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp., or Serratia marcescens: a pilot multi-center randomized controlled trial (MERINO-2). Open Forum Infect Dis. 2021.
35. Stewart A, Henden A Infectious complications of CAR T-cell therapy: A clinical update. Ther Adv Infect Dis. 2021.
36. Isler B, Harris PNA, Stewart A, Paterson DL An Update on Cefepime and its Future Role in Combination with Novel β-Lactamase Inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa – Author’s Response. J Antimicrob Chemother. 2021.
37. Stewart A, Stewart AGA An update on the laboratory diagnosis of Rickettsia spp. infection. Pathogens. 2021.
38. Simos P, Stewart A Sexually acquired reactive arthritis secondary to macrolide-resistant Mycoplasma genitalium urethritis. Intern Med J. 2021.
39. Stewart A, Henderson A, Bauer M, Paterson DL, Harris PNA Activity of temocillin against third generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial. JAC Antimicrob Resist. 2021.
40. Laupland KB, Stewart A, Edwards F, Paterson DL, Coulter S, Heney C, George N, Harris PNA Shewanella species bloodstream infections in Queensland, Australia. Emerg Infect Dis. 2021.
41. Laupland KB, Stewart A, Edwards F, Harris PNA, Heney C, George N, Coulter S, Paterson DL Pasteurella species bloodstream infections in Queensland, Australia, 2000-2019. Eur J Clin Microbiol Infect Dis. 2022.
42. Tariq A, Stewart A, Teloken PE, Dunglison NT, Martin BF, Roberts MJ Painless penile periurethral polymicrobial abscess causing urinary retention. Urol Case Rep. 2022.
43. Simos P, Holland D, Stewart A, Isler B, Hughes I, Price N, Henderson A, Alcorn K Clinical prediction scores and the utility of time to blood culture positivity in stratifying the risk of infective endocarditis in Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2022.
44. Balcerek MI, Stewart A, Chapman P, Lazarus S Reducing the off-target endocrinologic adverse effects of azole antifungals - can it be done? Int J Antimicrob Agents. 2018.
45. Laupland KB, Paterson DL, Stewart A, Edwards F, Harris PNA Sphingomonas paucimobilis bloodstream infection is a predominantly community-onset disease with significant lethality. Int J Infect Dis. 2022.
46. Laupland KB, Paterson DL, Edwards F, Stewart A, Harris PNA Morganella morganii: An emerging cause of bloodstream infections. Microbiol Spectr. 2022.
47. Tariq A, Stewart A, Desai DJ, Britton S, Dunglison N, Ester R, Roberts MJ Periurethral Abscess Aetiology, Risk Factors, Treatment options and their Outcomes: A Systematic Review. Curr Urol. 2022.
48. Stewart A, Isler B, Paterson DL An Australian perspective on Antimicrobial Stewardship Programs and Transplantation. Transpl Infect Dis. 2022.
49. Isler B, Vatansever C, Özer B, Çınar G, Aslan AT, Stewart A, Simos P, Falconer C, Bauer MJ, Forde B, Harris PNA, Şimşek F, Tülek N, Demirkaya H, Menekşe S, Akalin H, Balkan İİ, Aydın M, Tigen ET, Demir SK, Kapmaz M, Keske Ş, Doğan Ö, Arabacı Ç, Yağcı S, Hazırolan G, Bakır VO, Gönen M, Saltoğlu N, Azap A, Azap Ö, Akova M, Ergönül Ö, Paterson DL, Can F Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolates. Diagn Microbiol Infect Dis. 2022.
50. Laupland KB, Harris PNA, Stewart A, Edwards F, Paterson DL Culture-based determinants and outcome of Staphylococcus aureus bloodstream infections. Diagn Microbiol Infect Dis. 2022.
51. Madden E, McCarthy KL, Bell SC, Olagoke A, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart A, Subedi S, Choong K, Fraser TA, Sarovich DS, Price EP Rapid fluoroquinolone resistance detection in Pseudomonas aeruginosa using mismatch amplification mutation assay-based real-time PCR. J Med Microbiol. 2022.
52. Parkes-Smith J, Bauer MJ, Bergh H, Eidan A, Forde BM, Hilton J, Kidd TJ, Schmidt C, Stewart A, Harris PNA A fatal case of Aspergillus felis infection in an immunocompetent host. Access Microbiol. 2022.
53. Stewart A, Schlebusch S, Vlack S, McMahon J, Sullivan, Pyke A, Hajkowicz H First Case of Monkeypox Virus Infection Diagnosed in Queensland, Australia – Clinical and Molecular Aspects. Med J Aust. 2022.
54. Stewart A, Roberts JA, Forde BM, Bergh H, Kidd TJ, Wright H, Harris PNA Treatment failure due to adaptive resistance mechanisms in a severe and complicated bloodstream infection due to Elizabethkingia meningoseptica. Microb Drug Resist. 2022.
55. Symons T, Straiton N, Gagnon R, Littleford R, Campbell AJ, Bowen AC, Stewart A, Tong SYC, Davis JS Consumer Perspectives on Simplified, Layered Consent for a Low Risk, but Complex Pragmatic Trial. Trials. 2022.
56. Stewart A, Isler B, Simos P, Farquhar D, George N, Golmayo M, Heney C Aspergillus species causing invasive fungal disease in Queensland, Australia. Mycopathologia. 2023.
57. Divithotewala C, Sweeney EL, Burke A, Graves B, Stewart A, Whiley D, Heney C, Hopkins PM, Chambers DC Mycoplasma hominis and Ureaplasma urealyticum infections in the immediate post lung transplant period. Transpl Infect Dis. 2023.
58. Stewart A, Chen SCA, Hamilton K, Harris-Brown T, Korman TM, Figtree M, Worth LJ, Kok J, Van der Poorten D, Blyth K, Slavin MA, Paterson DL Clostridioides difficile infection: clinical practice and health outcomes in six large tertiary hospitals in Eastern Australia. Open Forum Infect Dis. 2023.
59. Stewart A, Heney C, Paterson DL, DL, Harris PNA, PNA, Edwards F, Laupland KB Scedosporium species and Lomentospora prolificans fungaemia is uniformly fatal in patients with haematological malignancy. Intern Med J. 2023.
60. Stewart A, Bauer MJ, Butkiewicz D, Hinton A, Henderson A, Harris PNA, Paterson DL In vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial. Int J Antimicrob Agents. 2023.
61. Peters N, Williamson F, Bauer M, Llewellyn S, Snelling P, Marsh N, Harris PNA, Stewart A, Rickard CM Comparison of low-level to high-level disinfection in eliminating microorganisms from ultrasound transducers used on skin: a non-inferiority randomised controlled trial. J Ultrasound Med. 2023.
62. Stewart A, Laupland KB, Tabah A Central line associated and primary bloodstream infections. Curr Opin Crit Care. 2023.
63. Stewart A, Kotton CN What’s New: Updates on Cytomegalovirus in Solid Organ Transplantation. Transplantation. 2023.
64. Peri AM, O’Callaghan K, Rafiei N, Graves B, Sinclair H, Brischetto A, Parkes-Smith J, Eustace M, Davidson N, Tabah A, Stewart A, Chatfield MD, Harris PNA, Paterson DL Persistence of detectable pathogens by culture independent systems (T2 Magnetic Resonance) in patients with bloodstream infection: prognostic role and possible clinical implications. Clinical Infectious Diseases. 2023.
65. Peri AM, O’Callaghan K, Rafiei N, Graves B, Sinclair H, Brischetto A, Parkes-Smith J, Eustace M, Davidson N, Tabah A, Stewart A, Chatfield MD, Harris PNA, Paterson DL Persistence of detectable pathogens by culture independent systems (T2 Magnetic Resonance) in patients with bloodstream infection: prognostic role and possible clinical implications. Clinical Infectious Diseases. 2023.
66. Douglas AP, Stewart A, Halliday CL, Chen SCA Outbreaks of fungal infections in hospitals: epidemiology, detection and management. J Fungi. 2023.
67. Chan S, Cheung CY, Stewart A, Chen SCA, Kotton CN, Hand J, Craig J, Hawley C, Johnson D, Wong G Interventions for preventing urinary tract infections in kidney transplant recipients. Cochrane Database Syst Rev. 2023.
68. Peri AM, Rafiei N, O’Callaghan K, Brischetto A, Graves B, Sinclair H, Eustace M, Lim K, Parkes-Smith J, Stewart A, Davidson N, Tabah A, Bergh H, Chatfield MD, Harris PNA, Paterson DL Host response signature trends in persistent bacteraemia and metastatic infection due to Staphylococcus aureus and Gram-negative bacilli: a prospective multicentre observational study. Infectious Diseases. 2023.
69. Sheehy J, Scott AP, Henden AS, Kennedy G, Redmond AM, Stewart A Low rates of complications and beta-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy. J Antimicrob Chemother. 2020.
70. Stewart A, Kotton CN Impact of Blood Donation Biovigilance and Transfusion Transmitted Infections on Organ Transplantation. Transpl Infect Dis. 2024.
71. Stewart A, Kotton CN Another viral infection linked to post-transplant diabetes mellitus? Transplantation. 2024.
72. Fahmy M, Stewart A, Tey SK, Hajkowicz K Elizabethkingia bloodstream infections in severely immunocompromised patients: Persistent, relapsing and associated with high mortality. JAC Antimicrob Resist. 2024.
73. Stewart A, Simos P, Sivabalan P, Escolà-Vergé L, Garnham K, Isler B ESGBIES study group. An update on recent clinical trial data in bloodstream infection. Antibiotics. 2024.
74. Bassetti M, Stewart A, Bartalucci C, Vena A, Giacobbe DR, Roberts J Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2024.
75. Stewart A, Chambers DC Primary graft dysfunction, dysbiosis and innate immune activation after lung transplantation. J Heart Lung Transplant. 2024.
76. Babady NE, Chiu CY, Craney A, Gaston DC, Hicklen RS, Hogan CA, John TM, Stewart A Diagnosis of invasive fungal diseases by metagenomic next-generation sequencing: are we there yet? Expert Rev Mol Diagn. 2024.
77. Portales CC, Stewart A, Kotton CN Yersinia enterocolitica Pneumonia in a Heart Transplant Recipient. Transpl Infect Dis. 2024.
78. Stewart A, Edwards F, Harris PNA, Paterson DL, Laupland KB Risk of mortality in Fusobacterium species bloodstream infection from a large Australian cohort. Eur J Clin Microbiol Infect Dis. 2024.
79. Stewart A, Harris PNA, Edwards F, Behzad K, Paterson DL, Laupland KB Klebsiella pneumoniae species complex bloodstream infection in adult patients: changing epidemiology and determinants of poor outcomes. Infection. 2024.
80. Stewart A, Fishman JA Surveillance and Prevention of Infection in Clinical Xenotransplantation. Clin Microbiol Rev. 2024.
81. Roberts DM, Liu X, Parker SL, Burke A, Peek J, Carland JE, Murnion B, Seah V, Wallis SC, Sumi CD, Pandey S, Buscher H, Byrne A, Sandaradura I, Bowen D, Holz S, Stewart A, Hajkowicz K, Roberts JA Population pharmacokinetic modelling of remdesivir and its metabolite GS-441524 in hospitalised patients with COVID-19. Clin Pharmacokinet. 2025.
82. Laupland KB, Stewart A, Edwards F, Harris PNA, Coulter S Community-onset bloodstream infection among people with opioid use disorders: A twenty-year population-based cohort study in Queensland, Australia. Infectious Diseases. 2025.
83. Stewart A, Chemaly RF Unravelling T cell immunity in CAR-T therapy: Implications for influenza vaccination. Transplant Cell Ther. 2025.
84. Stewart A, Harris PNA, Graham RMA, Jennison AV, Schlebusch S, Kakkanat A, Harris-Brown T, Paterson DL, Forde BM Differences in antimicrobial resistance gene abundance and microbial diversity of the gut microbiome in patients on antibiotics enrolled in a clinical trial. Ther Adv Infect Dis. 2025.
85. Stewart A, Laupland KB, Edwards F, Koo S, Hammond SP, Harris PNA, Paterson DL, Slavin MA, Chen SCA Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance. J Infect. 2025.
86. Stewart A, Laupland KB, Edwards F, Gassiep I, Koo S, Hammond SP, Chen SCA, Slavin MA Clinical characteristics and outcomes in patients with cryptococcaemia from a large population-based cohort. Mycoses. 2025.
87. Stewart A, Laupland KB, Edwards F, Slavin MA, Chen SCA Epidemiology, significance and clinical outcomes of bloodstream infections caused by non-Candida and non-Cryptococcus yeasts. Mycoses. 2025.
88. Paterson DL, Sulaiman H, Liu P-Y, Chatfield MD, Yilmaz M, Salmuna ZN, Mazlan MZ, Anunnatsiri S, Sirijatuphat R, Chotiprasitsakul D, Lye DC, Somani J, Kalimuddin S, Aslan AT, Thamlikitkul V, Lee Y-T, Yang YS, Lin Y-T, Ramli WNW, Tseng C-H, Archuleta S, Chan YFZ, Forde BM, Wright H, Stewart A, Ramsay K, Ling W, Rossi V, Harris-Brown T, Harris PNA A randomised trial of cefiderocol versus standard therapy for gram-negative bacterial bloodstream infection. Lancet Infect Dis. 2025.
89. Stewart A, Allos H, John TM Microbial cell-free DNA for diagnosis of bacterial and fungal infection in the immunocompromised host – what do we know? Curr Opin Infect Dis. 2025.
90. Stewart A, Edwards F, Laupland KB The impact of geography and antimicrobial resistance on the incidence and outcomes of Elizabethkingia species bloodstream infection.
91. Stewart A, Edwards F, Laupland KB Bloodstream infection and risk for plasma cell neoplasms.
92. Stewart A, Douglas AP, Kidd SE, Salmanton-Garcia J, Cornely OA, Morris AJ, Halliday CL, Chen SCA Mycological testing in Australasian clinical mycology laboratories.

Abstracts

1. Stewart A. "The use of procalcitonin to monitor resolution of infection in gram negative bacteraemia and sepsis". RBWH Healthcare Symposium.
2. Stewart A. “Lactococcus garvieae in urine: An emerging pathogen’s spectrum of disease”. ASID ASM.
3. Stewart A. “The role of procalcitonin in the monitoring of Gram negative bacteraemia”. ASA Antimicrobials 2015.
4. Stewart A. “Queensland tick typhus in Northern Brisbane: A 15-year retrospective study of epidemiology, clinical features and outcomes”. ASID ASM.
5. Stewart A. “Evidence of clinical response and stability of ceftolozane/tazobactam used to treat a carbapenem-resistant Pseudomonas aeruginosa lung abscess on an outpatient antimicrobial program”. ASA Antimicrobials 2018.
6. Stewart A. “Molecular epidemiology of extended-spectrum beta-lactamase (ESBL)- producing Enterobacteriaceae on the Sunshine Coast”. ASID ASM.
7. Stewart A. “Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC beta-lactamase-producing Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: a pilot multi-centre randomised controlled trial”. 30th ECCMID.
8. Stewart A. “Differences in antimicrobial resistance gene abundance and microbial diversity of the gut microbiome in patients on antibiotics enrolled in a clinical trial”. 33rd ECCMID.
9. Stewart A. “Oral third generation cephalosporins plus clavulanate activity in ESBL-producing Enterobacteriaceae isolates from a clinical trial”. 33rd ECCMID.
10. Stewart A. “Severe sepsis and other complications of acute Rickettsia australis infection and Queensland tick typhus”. XIX International Congress for Tropical Medicine and Malaria 2016.
11. Stewart A. “In Vitro Activity of Oral Third Generation Cephalosporin and Clavulanic Acid Combinations against Ceftriaxone-Resistant Enterobacterales”. ASM Microbe 2020.
12. Stewart A. “Using Whole-Genome Sequencing and a Pentaplex Real-Time PCR to Characterize Third-Generation Cephalosporin-Resistant Enterobacteriaceae from Southeast Queensland, Australia”. ASM Microbe 2020.
13. Stewart A. “Whole Genome Sequencing for Antimicrobial Resistance Mechanisms, Virulence Factors and Clonality in Invasive Streptococcus agalactiae Blood Culture Isolates Recovered in Australia”. ASM Microbe 2020.
14. Stewart A. “Severe hyperammonemia and encephalopathy caused by Cryptococcus neoformans infection in a renal transplant patient”. ASID ASM 2021.
15. Stewart A. “Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae from Southeast Queensland, Australia”. ASID ASM 2021.
16. Stewart A. “Meropenem versus piperacillin-tazobactam for treatment of bloodstream infections caused by AmpC beta-lactamase producing Enterobacterales: a pilot randomised controlled trial (MERINO 2)”. ASID ASM 2021.
17. Stewart A. “In vivo development of fluoroquinolone and rifamycin resistance in prolonged Elizabethkingia meningoseptica bloodstream infection”. 32nd ECCMID.
18. Stewart A. “Third-generation cephalosporin-resistant Klebsiella pneumoniae complex bloodstream infection in adult patients: changing epidemiology and determinants of poor outcomes”. ASA Antimicrobials 2024.
19. Stewart A. “Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals differences in mortality, recurrence and resistance”. 22nd Congress of the International Society for Human and Animal Mycology.
20. Stewart A. Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals differences in mortality, recurrence and resistance. 35th ESCMID Global.